Skip to main content
Clinical Trials/KCT0007590
KCT0007590
Recruiting
未知

A Noninterventional Exit Survey Study to Understand Meaningful Change in Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma who Discontinued Treatment in the SPOTLIGHT or GLOW Study

Astellas Korea0 sites14 target enrollmentTBD
ConditionsNeoplasms

Overview

Phase
未知
Intervention
Not specified
Conditions
Neoplasms
Sponsor
Astellas Korea
Enrollment
14
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Observational Study
Sex
All

Investigators

Sponsor
Astellas Korea

Eligibility Criteria

Inclusion Criteria

  • 1\. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written informed consent and privacy language as per national regulations (e.g., HIPAA Authorization for US sites) must be obtained from the subject or legally authorized representative (if applicable) prior to any study\-related procedures.
  • 2\. Subjects who are within 30 days following the treatment discontinuation visit(s) (both study treatments) in the SPOTLIGHT (8951\-CL\-0301\) or GLOW (8951\-CL\-0302\) study.

Exclusion Criteria

  • 1\. Subject has any concurrent disease, infection or comorbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data in the opinion of the investigator.

Outcomes

Primary Outcomes

Not specified

Similar Trials